AbbVie’s Apogee deal is under the microscope

Deal math, but make it spicy

AbbVie’s proposed buyout of Apogee Therapeutics is already drawing legal heat. Kahn Swick & Foti says it’s investigating whether the $135.11-per-share cash offer and the process behind it actually did shareholders justice.

That may sound like standard-issue M&A drama — and honestly, it kind of is — but these investigations can still matter. They can slow down a deal, add settlement risk, or at least make the path from announcement to closing a little bumpier than management probably hoped.

Why investors should care

For AbbVie, the headline risk is mostly about deal execution. If this turns into a bigger legal mess, it could complicate timing or add costs. For Apogee holders, the question is simpler: is this the best price they could have gotten, or is someone trying to sell the car while the engine is still warm?

• The deal is structured as an all-cash acquisition of Apogee
• The offer price is $135.11 a share
• KSF is scrutinizing both valuation and process

Big picture

This is the kind of news that doesn’t usually rewrite the whole investment thesis, but it can add friction at the worst possible moment. In M&A land, even a “routine” investigation is never exactly routine.